Glycosaminoglycan sulodexide decreases albuminuria in diabetic patients.

Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. J Am Soc Nephrol (2011) 1.66

Characterization of anticoagulant heparinoids by immunoprofiling. Glycoconj J (2007) 0.99

Sulodexide decreases albuminuria and regulates matrix protein accumulation in C57BL/6 mice with streptozotocin-induced type I diabetic nephropathy. PLoS One (2013) 0.84

Preclinical and clinical evidence of nephro- and cardiovascular protective effects of glycosaminoglycans. Arch Med Sci (2010) 0.82

Therapeutic Modalities in Diabetic Nephropathy: Future Approaches. Open J Nephrol (2012) 0.81

Anti-proteinuric effect of sulodexide in immunoglobulin a nephropathy. Yonsei Med J (2011) 0.81

Effect of sulodexide on urinary biomarkers of kidney injury in normoalbuminuric type 2 diabetes: a randomized controlled trial. J Diabetes Res (2015) 0.80

Sulodexide therapy for the treatment of diabetic nephropathy, a meta-analysis and literature review. Drug Des Devel Ther (2015) 0.80

Nephroprotective action of glycosaminoglycans: why the pharmacological properties of sulodexide might be reconsidered. Int J Nephrol Renovasc Dis (2010) 0.78

Use of low-dose sulodexide in IgA nephropathy patients on renin-angiotensin system blockades. Kidney Res Clin Pract (2012) 0.75

The efficacy of self-monitoring of blood glucose in the management of patients with type 2 diabetes treated with a gliclazide modified release-based regimen. A multicentre, randomized, parallel-group, 6-month evaluation (DINAMIC 1 study). Diabetes Obes Metab (2008) 1.59

Pathogenesis of angiopathy in diabetes. Acta Diabetol (2003) 0.88

Comparison of insulin sensitivity in patients with insulinoma and obese Type 2 diabetes mellitus. Horm Metab Res (1996) 0.88

Anti-GAD-positive patients with type 1 diabetes mellitus have higher prevalence of autoimmune thyroiditis than anti-GAD-negative patients with type 1 and type 2 diabetes mellitus. Physiol Res (2004) 0.87

Development of a multiplex-PCR for rapid detection of the enteric pathogens Lawsonia intracellularis, Brachyspira hyodysenteriae, and Brachyspira pilosicoli in porcine faeces. Lett Appl Microbiol (2006) 0.85

The effect of glycosaminoglycan sulodexide on oxidative stress and fibrinolysis in diabetes mellitus. Sb Lek (1998) 0.84

Insulin action and fibrinolysis influenced by vitamin E in obese Type 2 diabetes mellitus. Diabetes Res Clin Pract (1999) 0.83

Relationship of oxidative stress and fibrinolysis in diabetes mellitus. Diabet Med (1996) 0.80

[Collagenofibrotic glomerulopathy--rare glomerulonephritis]. Vnitr Lek (2006) 0.79

Comparison of N-acetyl-beta-glucosaminidase and albuminuria with clinical finding of microangiopathy in type I diabetes mellitus. Clin Chim Acta (1987) 0.77

Early changes of serum N-acetyl-beta-glucosaminidase, tissue plasminogen activator and erythrocyte superoxide dismutase in relation to retinopathy in type 1 diabetes mellitus. Clin Chim Acta (1994) 0.76

[Levels of tissue-type plasminogen activator (T-PA), its inhibitor (PAI-1) and fibrinogen in the blood of patients with type 1 and 2 diabetes mellitus]. Cas Lek Cesk (1996) 0.76

Is a mutation of the beta 3-adrenergic receptor gene related to non-insulin-dependent diabetes mellitus and juvenile hypertension in the Czech population? Ann N Y Acad Sci (1997) 0.76

[A genetically defined model for testing teratogenicity in vivo]. Sb Lek (1988) 0.75

Influence of ACE inhibition on insulin resistance. Nephrol Dial Transplant (1995) 0.75

[The significance of ergometric examinations in type I diabetics]. Sb Lek (1987) 0.75

Relationship of serum N-acetyl-beta-glucosaminidase activity to oxidative stress in diabetes mellitus. Clin Chim Acta (1999) 0.75

[The level of diabetic compensation and endogenous secretion of insulin in newly diagnosed diabetics. Prospective study: Part 1]. Vnitr Lek (1999) 0.75

N-acetyl-beta-glucosaminidase and albuminuria in normal and diabetic pregnancies. Clin Chim Acta (1989) 0.75

[Type 1 diabetes mellitus in the aged]. Vnitr Lek (1998) 0.75

[Present findings on the pathogenesis of type 2 diabetes]. Vnitr Lek (1987) 0.75

[Fiber in the diabetic diet]. Vnitr Lek (1989) 0.75

[Personal experience with the Mono type of insulin--clinical study]. Vnitr Lek (1996) 0.75

[Changes in indicators of humoral immunity in patients with insulin-dependent diabetes]. Cas Lek Cesk (1985) 0.75

[Clinical experience with changing type I diabetics from animal to human insulin administered by the NovoPen 3 applicator]. Vnitr Lek (1997) 0.75

[Endoscopic retrograde cholangiopancreatography and disorders of glucose tolerance in chronic pancreatitis]. Cas Lek Cesk (1985) 0.75

[Hypokalemic renal tubular syndromes: pathogenesis, diagnosis and therapy]. Bratisl Lek Listy (1999) 0.75

[Prevention of progression in nephropathies]. Bratisl Lek Listy (1994) 0.75

[C-peptide in type I diabetics]. Vnitr Lek (1986) 0.75

[Acylpyrin and glucose homeostasis in diabetes mellitus]. Cas Lek Cesk (1988) 0.75

[A protein-restricted diet combined with ACE inhibitors does not improve insulin sensitivity in renal hypertension]. Vnitr Lek (1996) 0.75

[C-peptide and the importance of its determination]. Vnitr Lek (1986) 0.75

[Pharmacodynamics of angiotensin-converting enzyme inhibitors]. Vnitr Lek (1996) 0.75

[Relation between plasma levels of IGF-I, leptin and TNF-alpha in diabetics]. Cas Lek Cesk (1999) 0.75

Laboratory detection of the early stages of diabetic nephropathy. Acta Univ Carol Med (Praha) (1989) 0.75

[Non-specific organ autoantibodies in patients with insulin-dependent diabetes]. Sb Lek (1983) 0.75

[Significance of the determination of C-peptide in type 2 diabetes]. Vnitr Lek (1987) 0.75

[Changes in NT-proBNP levels in patients with atrial fibrillation related to heart failure]. Vnitr Lek (2010) 0.75

Haemostasis, cytoadhesive molecules (sE-selectin and sICAM-1) and inflammatory markers in non-insulin dependent diabetes mellitus (NIDDM). Sb Lek (1998) 0.75

[Plasma leptin levels in patients with kidney diseases of various etiologies]. Cas Lek Cesk (1999) 0.75

[The effect of Sinecal fiber on compensation in type 2 diabetics]. Vnitr Lek (1989) 0.75

[The role of platelet-derived growth factor in progression of nephropathy]. Vnitr Lek (1996) 0.75

[Non-insulin-dependent diabetes mellitus--strategies and problems in genetic research]. Vnitr Lek (1996) 0.75

The effect of fasting and vitamin E on insulin action in obese type 2 diabetes mellitus. Ann N Y Acad Sci (1997) 0.75

[The significance of determining the daily blood glucose profile for the evaluation of compensation in diabetes]. Sb Lek (1985) 0.75